TLR agonists as adjuvants for cancer vaccines

Advances in Experimental Medicine and Biology

Volumn 1024, Issue , 2017, Pages 195-212

  Li, Ji Kun ^a   Balic, Jesse J ^b,c   Yu, Liang ^a,b,c   Jenkins, Brendan ^b,c  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Adjuvant; Agonist; Clinical trial; Toll like receptor

Indexed keywords

AGATOLIMOD; BCG VACCINE; BEVACIZUMAB; CADI 05; CANCER VACCINE; CMB 305; COBITOLIMOD; DEFOSLIMOD; ENTOLIMOD; G 100; HILTONOL; IBRUTINIB; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; IMM 101; IMO 2055; INDOMETACIN; ISS 1018; KAPPAPROCT; LEFITOLIMOD; MOTOLIMOD; PICIBANIL; POLYINOSINIC POLYCYTIDYLIC ACID; RECOMBINANT HEPATITIS B VACCINE; RESIQUIMOD; RINTATOLIMOD; SD 101; SIPULEUCEL T; TMX 101; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; WART VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT;

ACTINIC KERATOSIS; ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BASAL CELL CARCINOMA; BLADDER CANCER; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COLON CANCER; COLORECTAL CANCER; CONDYLOMA ACUMINATUM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANCER; FEVER; FOLLICULAR LYMPHOMA; GENITAL TRACT CANCER; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPOTENSION; LEUKEMIA; LIVER CANCER; LIVER METASTASIS; LUNG METASTASIS; LYMPHOMA; MALIGNANT NEOPLASM; MELANOMA; MERKEL CELL CARCINOMA; METASTATIC BREAST CANCER; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MOUTH CANCER; NON MELANOMA SKIN CANCER; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; RENAL CELL CARCINOMA; SKIN METASTASIS; SMALL CELL LUNG CANCER; SOLID MALIGNANT NEOPLASM; STOMACH CANCER; TISSUE REPAIR; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; AGONISTS; IMMUNOLOGY; NEOPLASM;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; HUMANS; NEOPLASMS; TOLL-LIKE RECEPTORS;

EID: 85029668940     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-981-10-5987-2_9     Document Type: Chapter

References (106)

1. Gay NJ, Gangloff M (2007) Structure and function of toll receptors and their ligands. Annu Rev Biochem 76(1):141–165
2. Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21(1):335–376
3. Janeway CA (1989) Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54:1–13
4. Hernandez C, Huebener P, Schwabe RF (2016) Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene 35(46):5931–5941
5. Kadowaki N et al (2001) Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194(6):863–870
6. Adams S (2009) Toll-like receptor agonists in cancer therapy. Immunotherapy 1(6):949–964
7. Hayashi F, Means TK, Luster AD (2003) Toll-like receptors stimulate human neutrophil function. Blood 102(7):2660–2669
8. + regulatory T cell function. Science 309(5739):1380–1384
9. Alison CW, Brendan JJ (2015) Inflammatory and non-inflammatory roles for toll-like receptors in gastrointestinal cancer. Curr Pharm Des 21(21):2968–2977
10. Kovach MA, Standiford TJ (2011) Toll like receptors in diseases of the lung. Int Immunopharmacol 11(10):1399–1406
11. LaRue H et al (2013) Toll-like receptors in urothelial cells—targets for cancer immunotherapy. Nat Rev Urol 10(9):537–545
12. Paulos CM et al (2007) Toll-like receptors in tumor immunotherapy. Clin Cancer Res 13(18):5280–5289
13. Dowling JK, Mansell A (2016) Toll-like receptors: the Swiss army knife of immunity and vaccine development. Clin Translat Immunol 5(5):e85
14. Human Papillomavirus (HPV) Vaccines. National Cancer Institute (NCI) (2009). 2009–10-22 (Retrieved 2009–11–11)
15. Hepatitis B vaccines WHO position paper. Weekly epidemiological record (2009) 40(84):405–420
16. Silva A et al (2015) The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo. J Immunol 194(5):2199–2207
17. Vasilakos JP, Tomai MA (2013) The use of toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev Vaccines 12(7):809–819
18. Mutwiri G et al (2011) Combination adjuvants: the next generation of adjuvants? Expert Rev Vaccines 10(1):95–107
19. Martins KAO, Bavari S, Salazar AM (2015) Vaccine adjuvant uses of poly-IC and derivatives. Expert Rev Vaccines 14(3):447–459
20. Banday AH, Jeelani S, Hruby VJ (2015) Cancer vaccine adjuvants – recent clinical progress and future perspectives. Immunopharmacol Immunotoxicol 37(1):1–11
21. Walter A et al (2013) Aldara activates TLR7-independent immune defence. Nat Commun 4:1560
22. Spaner DE et al (2009) A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia 24(1):222–226
23. Jasani B, Navabi H, Adams M (2009) Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 27(25–26):3401–3404
24. Vacchelli E et al (2012) Trial watch: FDA-approved toll-like receptor agonists for cancer therapy. OncoImmunology 1(6):894–907
25. Galluzzi L et al (2012) Trial watch: experimental toll-like receptor agonists for cancer therapy. OncoImmunology 1(5):699–739
26. Brackett CM et al (2016) Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Proc Natl Acad Sci 113(7):E874–E883
27. Musch E et al (2013) Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity. Inflamm Bowel Dis 19(2):283–292
28. Dalgleish AG et al (2016) Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br J Cancer 115(7):789–796
29. Smith DA et al (2014) Antitumor activity and safety of combination therapy with the toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy. Cancer Immunol Immunother 63(8):787–796
30. Friedberg JW et al (2009) Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 146(3):282–291
31. Isambert N et al (2013) Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer 13(1):172
32. Vacchelli E et al (2013) Trial watch: toll-like receptor agonists for cancer therapy. OncoImmunology 2(8):e25238
33. Wang S et al (2016) Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc Natl Acad Sci 113(46):E7240–E7249
34. Donin NM et al (2017) A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urol Oncol Semin Orig Investig 35(2):39.e1–39.e7
35. Lu H et al (2012) VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res 18(2):499–509
36. Mount A et al (2013) Combination of adjuvants: the future of vaccine design. Expert Rev Vaccines 12(7):733–746
37. Hughes AL, Piontkivska H (2008) Functional diversification of the Toll-like receptor gene family. Immunogenetics 60(5):249–256
38. Roach JC et al (2005) The evolution of vertebrate toll-like receptors. Proc Natl Acad Sci U S A 102(27):9577–9582
39. Dowling JK, Dellacasagrande J (2016) Toll-like receptors: ligands, cell-based models, and readouts for receptor action. In: McCoy CE (ed) Toll-like receptors: practice and methods. Springer, New York, pp 3–27
40. Murata M (2008) Activation of toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium Bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci 99(7):1435–1440
41. Netea MG et al (2004) Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol 172(6):3712–3718
42. Sun X et al (2013) TLR2 mediates helicobacter pylori–induced Tolerogenic immune response in mice. PLoS One 8(9):e74595
43. Yamazaki S et al (2011) TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 Lipopeptides in vivo. PLoS One 6(4):e18833
44. Nyirenda MH et al (2015) TLR2 stimulation regulates the balance between regulatory T cell and Th17 function: a novel mechanism of reduced regulatory T cell function in multiple sclerosis. J Immunol 194(12):5761–5774
45. McCartney S et al (2009) Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 206(13):2967–2976
46. Mitchell WM (2016) Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/ myalgic encephalomyelitis (CFS/ME). Expert Rev Clin Pharmacol 9(6):755–770
47. Caskey M et al (2011) Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med 208(12):2357–2366
48. Lampkin BC et al (1985) Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-l-lysine and carboxymethyl cellulose in the treatment of children with acute leukemia and Neuroblastoma: a report from the Children’s cancer study group. Cancer Res 45(11 Part 2):5904–5909
49. Sabbatini P et al (2012) Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 18(23):6497–6508
50. + T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res 1(5):340–350
51. Takeoka T et al (2017) NY-ESO-1 protein cancer vaccine with poly-ICLC and OK-432: rapid and strong induction of NY-ESO-1-specific immune responses by poly-ICLC. J Immunother 40(4):140–147
52. + T-cell responses in WHO grade 2 low-grade Glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res 21(2):286–294
53. Chen T et al (2009) Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol 182(3):1449–1459
54. Apetoh L et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13(9):1050–1059
55. Cluff CW (2013) Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Austin: Landes Bioscience, p 2000–2013
56. Talat Iqbal N, Hussain R (2014) Non-specific immunity of BCG vaccine: A perspective of BCG immunotherapy. Trials in Vaccinology 3:143–149
57. Coleman MM, Keane J, Mills KHG (2010) Editorial: Tregs and BCG—dangerous liaisons in TB. J Leukoc Biol 88(6):1067–1069
58. Ovchinnikova OA et al (2014) Mycobacterium bovis BCG killed by extended freeze-drying induces an immunoregulatory profile and protects against atherosclerosis. J Intern Med 275(1):49–58
59. Iribarren K et al (2016) Trial watch: Immunostimulation with toll-like receptor agonists in cancer therapy. OncoImmunology 5(3):e1088631
60. Sato T et al (2016) M1 macrophage infiltrations and histological changes in the liver after portal vein embolization using fibrinogen and OK432 in the rat. Cell Immunol 303:66–71
61. Kenjo A et al (2016) Role of intratumoral infiltrating macrophages after transarterial immu-noembolization for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 23(5):298–304
62. Wada H et al (2014) Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 Antigen. J Immunother 37(2):84–92
63. Lambert SL et al (2012) Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl lipid A. PLoS One 7(12):e51618
64. Lu H, Jan ter Meulen JH (2016) Intratumoral injection of G100 (TLR4 agonist glucopyranosyl lipid A) modulates tumor microenvironment and induces CD8 T cell-dependent, systemic anti-tumor immunity AACR Annual Meeting, p 4885
65. Matzner P et al (2016) Perioperative treatment with the new synthetic TLR-4 agonist GLA-SE reduces cancer metastasis without adverse effects. Int J Cancer 138(7):1754–1764
66. SID B, Vandeven N et al (2015) Pilot study of intratumoral G100, toll-like receptor-4 (TLR4) agonist, therapy in patients with Merkel cell carcinoma (MCC). ASCO Meeting 33:3083
67. Faham A, Altin JG (2010) Antigen-containing liposomes engrafted with Flagellin-related peptides are effective vaccines that can induce potent antitumor immunity and immunothera-peutic effect. J Immunol 185(3):1744–1754
68. Sfondrini L et al (2006) Antitumor activity of the TLR-5 ligand Flagellin in mouse models of cancer. J Immunol 176(11):6624–6630
69. Garaude J et al (2012) Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med 4(120):120ra16–120ra16.
70. Cai Z et al (2011) Activation of Toll-like receptor 5 on breast cancer cells by Flagellin suppresses cell proliferation and tumor growth. Cancer Res 71(7):2466–2475
71. Yang H et al (2016) The toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. Oncotarget 7(3):2936–2950
72. Fukuzawa N et al (2011) A TLR5 agonist inhibits acute renal ischemic failure. J Immunol 187(7):3831–3839
73. Xu Y et al (2016) CBLB502 administration protects gut mucosal tissue in ulcerative colitis by inhibiting inflammation. Ann Trans Med 4(16):301
74. Burdelya LG et al (2008) An agonist of toll-like receptor 5 has Radioprotective activity in mouse and primate models. Science 320(5873):226–230
75. Burdelya LG et al (2013) Central role of liver in anticancer and radioprotective activities of toll-like receptor 5 agonist. Proc Natl Acad Sci 110(20):E1857–E1866
76. Reeh M et al (2013) Presence of the Coxsackievirus and adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis. Br J Cancer 109(7):1848–1858
77. Diebold SS et al (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303(5663):1529–1531
78. Wille-Reece U et al (2005) HIV Gag protein conjugated to a toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A 102(42):15190–15194
79. Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33(4):492–503
80. Tomai MA, Vasilakos JP (2011) TLR-7 and -8 agonists as vaccine adjuvants. Expert Rev Vaccines 10(4):405–407
81. Adams S et al (2012) Topical TLR7 agonist Imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res 18(24):6748–6757
82. Bath-Hextall F et al (2014) Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol 15(1):96–105
83. Bassukas ID, Gaitanis G (2014) Basal-cell carcinoma: no response versus relapse. Lancet Oncol 15(3):e104–e105
84. Lear JT (2014) Evidence-based treatment for low-risk basal cell carcinoma. Lancet Oncol 15(1):12–13
85. Sabado RL et al (2015) Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. Cancer Immunol Res 3(3):278–287
86. Smirnov D et al (2011) Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 29(33):5434–5442
87. Abhyankar MM et al (2017) Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica. Vaccine 35(6):916–922
88. Singh M et al (2014) Effective innate and adaptive Antimelanoma immunity through localized TLR7/8 activation. J Immunol 193(9):4722–4731
89. Kapp K et al (2016) Distinct immunological activation profiles of dSLIM ® and ProMune x00AE; depend on their different structural context. Immun Inflammation Dis 4(4):446–462
90. Yang B et al (2014) DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother 10(11):3153–3164
91. Hirsh V et al (2011) Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non–small-cell lung cancer. J Clin Oncol 29(19):2667–2674
92. Manegold C et al (2012) A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 23(1):72–77
93. Wittig B et al (2015) MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. Crit Rev Oncol/Hematol 94(1):31–44
94. Schmoll HJ, Riera-Knorrenschild J, Kopp HG et al (2015) Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: a subgroup with improved overall survival. J Clin Oncol 33(suppl 3):abstr 680
95. Schmoll H-J et al (2014) Maintenance treatment with the immunomodulator MGN1703, a toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol 140(9):1615–1624
96. Cunningham D, Zurlo A, Salazar R et al (2015) IMPALA, a randomized phase III study in patients with metastatic colorectal carcinoma: Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703. J Clin Oncol 33(suppl 3):abstr TPS791
97. Houot R, Levy R (2009) T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 113(15):3546–3552
98. Marabelle A, Kohrt H, Levy R (2013) Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clin Cancer Res 19(19):5261–5263
99. Barrett DM et al (2014) Chimeric antigen receptor therapy for cancer. Annu Rev Med 65(1):333–347
100. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264
101. Dajon M, Iribarren K, Cremer I (2017) Toll-like receptor stimulation in cancer: a pro- and anti-tumor double-edged sword. Immunobiology 222(1):89–100
102. Lu H (2014) TLR agonists for cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effects. Front Immunol 5:83
103. + stromal cells. J Immunol 193(5):2218–2229
104. Boes M, Meyer-Wentrup F (2015) TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells. Cancer Lett 361(1):49–56
105. Wang R-F, Wang HY (2017) Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res 27(1):11–37
106. Mullard A (2016) The cancer vaccine resurgence. Nat Rev Drug Discov 15(10):663–665